Stock Watch: Rare Diseases Beget Rare Profitability
Profits Elude Alnylam Despite Three Product Launches
Do rare disease drugs with tiny patient populations lie outside the profitability continuum that runs from small-molecule primary care products to specialist biologics?
You may also be interested in...
Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.
Novartis’s multiple sclerosis treatment Kesimpta has shot out of the gates and bidding fair to contribute generously to the firm’s coffers, while new cholesterol drug Leqvio struggles, Q1 results show.
Alnylam’s fourth-quarter and full-year 2019 earnings announcement was only one of eight announcements made by the company since early February. With the fundamental basis of its orphan drug business model still unvalidated by a profit, perhaps the more recent announcements are meant to distract investors’ attention with different metrics.